RANK and RANKL Expression in Tumors of Patients with Early Breast Cancer.

ABSTRACT:

Introduction

The receptor activator of nuclear factor-κB (RANK) pathway was associated with the pathogenesis of breast cancer. Several studies attempted to link the RANK/RANKL pathway to prognosis; however, with inconsistent outcomes. We aimed to further contribute to the knowledge about RANK/RANKL as prognostic factors in breast cancer. Within this study, protein expression of RANK and its ligand, RANKL, in the tumor tissue was analyzed in association with disease-free survival (DFS) and overall survival (OS) in a study cohort of patients with early breast cancer.

Patients and methods

607 samples of female primary and early breast cancer patients from the Bavarian Breast Cancer Cases and Controls Study were analyzed to correlate the RANK and RANKL expression with DFS and OS

SUBMITTER: Behrens A 

PROVIDER: S-EPMC10764119 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature